Abstract
This article describes the unique industrial - academic collaboration that has been running for four years between Janssen Pharmaceutica NV and the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) towards identifying the next generation of schizophrenia therapeutics. This was a true collaboration, with both entities engaged in chemistry, In vitro pharmacology, DMPK and In vivo behavioral pharmacology, and aligned to deliver a first-in-class clinical candidate (NME) and additional back-up molecules. Notably, a first NME was delivered in a rapid timeframe and targeted the novel mechanism of mGlu5 positive allosteric modulation. As with any true collaboration, both sides brought unique skills to the table - Janssen leveraged deep drug discovery expertise and infrastructure, while Vanderbilt brought deep knowledge of the chemistry and pharmacology of the target in addition to the ability to provide deep scientific insight into the mechanism behind target modulation. In this article, we will discuss the science which drove our collaboration as well as some key lessons learned.
Keywords: Metabotropic, mGlu5, schizophrenia, allosteric, positive allosteric modulator, glutamate, NMDA hypofunction.
Current Topics in Medicinal Chemistry
Title:A Unique Industrial – Academic Collaboration Towards the Next Generation of Schizophrenia Therapeutics
Volume: 14 Issue: 3
Author(s): Gregor J. Macdonald and Craig W. Lindsley
Affiliation:
Keywords: Metabotropic, mGlu5, schizophrenia, allosteric, positive allosteric modulator, glutamate, NMDA hypofunction.
Abstract: This article describes the unique industrial - academic collaboration that has been running for four years between Janssen Pharmaceutica NV and the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) towards identifying the next generation of schizophrenia therapeutics. This was a true collaboration, with both entities engaged in chemistry, In vitro pharmacology, DMPK and In vivo behavioral pharmacology, and aligned to deliver a first-in-class clinical candidate (NME) and additional back-up molecules. Notably, a first NME was delivered in a rapid timeframe and targeted the novel mechanism of mGlu5 positive allosteric modulation. As with any true collaboration, both sides brought unique skills to the table - Janssen leveraged deep drug discovery expertise and infrastructure, while Vanderbilt brought deep knowledge of the chemistry and pharmacology of the target in addition to the ability to provide deep scientific insight into the mechanism behind target modulation. In this article, we will discuss the science which drove our collaboration as well as some key lessons learned.
Export Options
About this article
Cite this article as:
Macdonald J. Gregor and Lindsley W. Craig, A Unique Industrial – Academic Collaboration Towards the Next Generation of Schizophrenia Therapeutics, Current Topics in Medicinal Chemistry 2014; 14 (3) . https://dx.doi.org/10.2174/1568026613666131127154443
DOI https://dx.doi.org/10.2174/1568026613666131127154443 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Prediction of Affective Responses in Aerobic Exercise Sessions
CNS & Neurological Disorders - Drug Targets The Anandamide Degradation System as Potential Target for the Treatment of Central Nervous System Related Disorders
Current Medicinal Chemistry - Central Nervous System Agents Dysfunction of Glutamate Receptors in Microglia May Cause Neurodegeneration
Current Alzheimer Research The Immunomodulatory Effects of Physical Activity
Current Pharmaceutical Design Psychoemotional Background of Temporomandibular Joint Dysfunction and Possible Drug Therapy
Letters in Drug Design & Discovery Protein Aggregation and Its Consequences for Human Disease
Protein & Peptide Letters Anti-Androgen Drugs in the Treatment of Obsessive-Compulsive Disorder: A Systematic Review
Current Medicinal Chemistry Patent Selections :
Recent Patents on Cardiovascular Drug Discovery Novel Anticancer Strategy Aimed at Targeting Shelterin Complexes by the Induction of Structural Changes in Telomeric DNA: Hitting two Birds with one Stone
Current Cancer Drug Targets Clinically Relevant Pharmacokinetic Herb-drug Interactions in Antiretroviral Therapy
Current Drug Metabolism Novel Anti-arrhythmic Medications in the Treatment of Atrial Fibrillation
Current Cardiology Reviews Advances in Peptide Pharmaceuticals
Current Pharmaceutical Biotechnology The Effects of Mindfulness-Based Interventions on Sleep Disturbance: A Meta-Analysis
Adolescent Psychiatry Pharmacological Neuroprotection after Perinatal Hypoxic-Ischemic Brain Injury
Current Neuropharmacology Cytotoxic T Lymphocyte Antigen 4 Gene +49 A/G (rs231775) Polymorphism and Susceptibility to Systemic Lupus Erythematosus
Current Rheumatology Reviews Small Molecules that Promote Neurogenesis in vitro
Recent Patents on CNS Drug Discovery (Discontinued) Epidemiology of Hypochondriasis and Health Anxiety: Comparison of Different Diagnostic Criteria
Current Psychiatry Reviews In Vivo Uptake of β-Amyloid by Non-Plaque Associated Microglia
Current Alzheimer Research Modelling Human Disease with Pluripotent Stem Cells
Current Gene Therapy CCR1 Antagonists: What Have We Learned From Clinical Trials
Current Topics in Medicinal Chemistry